“Our findings do not support a strategy of targeted Lp-PLA2 inhibition with darapladib in patients stabilized after an ACS event,” announced Michelle O’Donoghue MD, MPH, from Brigham and Women’s Hospital, Boston, and co-principal investigator of SOLID-TIMI 52 - the Stabilization Of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction trial.
“Prior to results of the current study, there was a large body of evidence to suggest that Lp-PLA2 inhibition would reduce the risk of future cardiovascular events,” Dr. O’Donoghue said. “It appeared biologically plausible, but unfortunately that hypothesis was not confirmed in the current study.”
“We are hopeful that alternate therapies that target inflammation will improve outcomes for patients with heart disease,” she added.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved